Q4 2025 Compugen Ltd Earnings Call Transcript
Key Points
- Compugen Ltd (CGEN) extended its cash runway into 2029 through a non-dilutive transaction with AstraZeneca, securing $65 million in upfront capital.
- The company initiated new clinical trials for its potential first-in-class anti-PVRIG COM701 and anti-IL-18 binding protein antibody GS-0321.
- Compugen Ltd (CGEN) presented promising clinical updates at ESMO and SITC conferences for COM701 and GS-0321, respectively.
- The company has a strong financial outlook with a cash balance of approximately $145.6 million as of December 31, 2025.
- Compugen Ltd (CGEN) reported a significant increase in revenues for 2025, totaling approximately $72.8 million, compared to $27.9 million in 2024.
- The interim analysis for the MAIA-ovarian trial has been delayed to Q1 2027, indicating potential challenges in trial progression.
- R&D expenses decreased slightly in 2025, which may suggest reduced investment in certain areas of research.
- The company's net profit for 2025 was largely influenced by the upfront payment from AstraZeneca, raising concerns about sustainable revenue sources.
- There is uncertainty regarding the timeline and requirements for the path to registration for COM701, as it depends on the totality of the data.
- The company is reliant on partnerships with AstraZeneca and Gilead for milestone payments, which introduces dependency on external entities for financial milestones.
Ladies and gentlemen, thank you for joining us today. Welcome to Compugen's fourth quarter and full year 2025 results conference call. At this time, all participants are in listen-only mode. An audio webcast of this call is available in the investor section of Compugen's website www.cgen.com. As a reminder, today's call is being recorded.
With us from the contingent team are Dr. Eran Ophir, President and CEO, and David Silberman, Chief Financial Officer, Dr. Michelle Mahler, Chief Medical Officer, will join for the Q&A. Before we begin, we would like to remind you that during this call, the company may make projections or forward-looking statements regarding future events, business outlook, development efforts, and their potential outcome, the company's discovery platform, anticipated progress and plans, results and timelines for our programs, including disclosure of clinical data, financial and accounting related matters.
As well as statements regarding our cash position and cash runway, we wish to caution you that such
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
